FDAsafety guidance66% confidence
FDA AP — LAMOTRIGINE (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Aurobindo Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA078947. Sponsor: TORRENT PHARMS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: LAMOTRIGINE.
Supporting Context
- Therapeutic area
- Neurology · Antiepileptic
- Sub-indication
- General
Related signal: Aurobindo Pharma's Lamotrigine ANDA Submission Receives AP Status